1755P A comprehensive study of the role of EIF1AX mutations in anaplastic thyroid carcinomas. Relationship with established mutational events, tumor progression and dedifferentiation

Abstract

Background: RET fusions occur in 10-20% of pts with PTC. RET fusion testing enables identification of pts who may benefit from targeted treatments [tx]. This study described real-world RET fusion testing patterns for pts with PTC in France [FR], Germany [DE], Italy [IT], Spain [ES] and the UK.Methods: Real-world data were drawn from the Adelphi Thyroid Cancer Disease Specific Programme TM e a point-in-time survey conducted between July-December 2020 primarily with oncologists and endocrinologists in clinical practice. Physicians completed patient record forms for up to the next 4 consulting adult PTC pts. Study variables included demographics, diagnostic testing patterns, test results, timing of testing, test modalities, and samples used.